Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro
- PMID: 8093352
Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro
Abstract
The phorbol esters induce differentiation of chronic lymphocytic leukemia (CLL) cells. Clinical use of this observation has been hampered by the fact that phorbol esters are also tumor promoters. In this study we demonstrate that another protein kinase C activator, without tumor promoting activity, has similar effects on CLL cells. Fresh leukemic cells from the peripheral blood of 13 patients with CLL were isolated and cultured in the absence (control) or presence of Bryostatin 1 or 12-0-tetradecanoylphorbol 13-acetate (TPA). Aliquots of cells were then analyzed after 24, 72 and 120 hours for morphological changes, acid phosphatase (ACP) and the co-expression of two hairy cell-associated surface antigens, CD22 and CD11c, by flow cytometry. Bryostatin 1 induced changes in shape and morphology similar to TPA, with adherence and increase in cell size, abundant cytoplasm and irregular cytoplasmic membrane. Both agents induced a statistically significant increase in the expression of CD22 and CD11c compared with control (p < 0.0008). There was no significant difference between the two agents in the degree of expression of these two markers. Both agents also induced ACP that was tartrate resistant (TRAP). These changes indicate that Bryostatin is as effective as TPA in inducing further differentiation of CLL cells to a hairy cell stage.
Similar articles
-
Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.Clin Cancer Res. 2000 Apr;6(4):1328-32. Clin Cancer Res. 2000. PMID: 10778958
-
Immune phenotype and some enzyme patterns in phorbol ester-induced chronic lymphocytic leukemia cells.Neoplasma. 1995;42(5):221-6. Neoplasma. 1995. PMID: 8552199
-
Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.Am J Hematol. 1992 Aug;40(4):264-9. doi: 10.1002/ajh.2830400405. Am J Hematol. 1992. PMID: 1354412
-
[Variant hairy-cell leukemia: immunophenotypic and ultrastructural study of a case].Sangre (Barc). 1991 Apr;36(2):135-9. Sangre (Barc). 1991. PMID: 1866652 Review. Spanish.
-
Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.Leuk Lymphoma. 1993 Jan;9(1-2):141-8. doi: 10.3109/10428199309148517. Leuk Lymphoma. 1993. PMID: 8477194 Review.
Cited by
-
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.Haematologica. 2012 May;97(5):771-9. doi: 10.3324/haematol.2011.049155. Epub 2011 Dec 16. Haematologica. 2012. PMID: 22180432 Free PMC article.
-
Functional proteomic analysis reveals roles for PKCδ in regulation of cell survival and cell death: Implications for cancer pathogenesis and therapy.Adv Biol Regul. 2020 Dec;78:100757. doi: 10.1016/j.jbior.2020.100757. Epub 2020 Sep 28. Adv Biol Regul. 2020. PMID: 33045516 Free PMC article.
-
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.Nat Commun. 2020 Apr 20;11(1):1879. doi: 10.1038/s41467-020-15742-7. Nat Commun. 2020. PMID: 32312992 Free PMC article.
-
Review of survival analyses published in cancer journals.Br J Cancer. 1995 Aug;72(2):511-8. doi: 10.1038/bjc.1995.364. Br J Cancer. 1995. PMID: 7640241 Free PMC article.
-
Management of chronic lymphocytic leukaemia.Drugs Aging. 2000 Jan;16(1):9-27. doi: 10.2165/00002512-200016010-00002. Drugs Aging. 2000. PMID: 10733261 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials